Additionally, some scholars have suggested that T2DM patients receiving insulin treatment may experience a longer disease duration, increased complications, poorer islet function, and hypoglycemia, all of which can contribute to brain impairment. The gene discussed is INS; the disease is type 2 diabetes mellitus.